PubMed Health⌕ Search

PubMed · 11670987

Palladium(II) Complexation by p-Cyclophane Receptors. A Solution and Solid State Study.

Abstract

The coordination properties of the macrocyclic ligands 1,4,7,16,19,22-hexamethyl-1,4,7,16,19,22-hexaaza[9.9]-p-cyclophane (L1) and 1,4,7-trimethyl-19,22,28,31-tetraoxa-1,4,7,14,23-pentaaza[9.25]-p-cyclophane (L2) have been studied by means of potentiometric and (1)H and (13)C measurements in aqueous solution. L1 is composed of two equal triamine binding units connected by p-phenylene spacers. L2 presents a similar molecular architecture, a triamine moiety of L1 being replaced by a cyclic N(2)O(4) binding unit. L1 can form both mono- and dinuclear complexes in aqueous solution, while L2 gives only mononuclear species. The potentiometric data indicate that in the L1 dinuclear complex each metal is coordinated by a triamine moiety. In the L2 mononuclear complex the Pd(II) ion is coordinated by the N(3) unit. The N(2)O(4) moiety does not show any binding ability toward Pd(II), but exhibits a high tendency to protonate. These solution data are confirmed by the crystal structures of [Pd(2)Cl(2)L1](ClO(4))(2).H(2)O (a) and [PdClL2H(2)(H(2)O)](ClO(4))(3) (b). In complex a, each Pd(II) ion is four coordinated by the three amine groups of the triaza moiety and a chloride anion, in a square planar geometry. In the mononuclear complex b, the metal is coordinated by the N(3) moiety, with a coordination environment almost equal to that found in complex a. The N(2)O(4) moiety is diprotonated and encapsulates in its cavity a water molecule, held by a hydrogen-bond network. The solution structures of the L1 and L2 complexes have been studied by means of (1)H and (13)C NMR measurements. The analysis of the NMR data reveals that the dinuclear L1 complex and the L2 mononuclear one show structural features in solution almost equal to those found in the solid state. Solution and solid state data indicate that the Pd(II) complexation gives a marked stiffening of the macrocyclic structures.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Andrea Bencini, Antonio Bianchi, Vieri Fusi, Claudia Giorgi, Piero Paoletti, Jose' Antonio Ramirez, Barbara Valtancoli. 1999-05-03. Palladium(II) Complexation by p-Cyclophane Receptors. A Solution and Solid State Study.. https://doi.org/10.1021/ic9810891

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Effectiveness of high-dose versus standard-dose influenza vaccines against hospitalisation according to frailty risk: a prespecified analysis of the randomised trial DANFLU-2.

BACKGROUND: Frailty is a major risk factor for influenza-related complications and can influence vaccine effectiveness. We aimed to assess the relative vaccine effectiveness (rVE) of high-dose (HD-IIV) versus standard-dose inactivated influenza vaccine (SD-IIV) in older adults aged 65 years or older according to frailty risk. METHODS: This study was a prespecified analysis of DANFLU-2, an open-label, individually randomised trial, conducted in Denmark during three consecutive influenza seasons (2022-23, 2023-24, and 2024-25). Adults aged 65 years or older were randomised (1:1) to the HD-IIV or SD-IIV group. The primary endpoint was hospitalisation for influenza or pneumonia. Frailty was defined according to the validated Hospital Frailty Risk Score (HFRS) based on ICD-10 codes within 10 years before randomisation. Participants were stratified into three HFRS categories, namely low (<5 points), intermediate (5-15 points), and high (>15 points) frailty risk. The rVE of HD-IIV versus SD-IIV against the primary endpoint was assessed across prespecified HFRS categories and treating HFRS as a continuous variable. Pearson's chi-square test was used to compare safety events across frailty risk groups and randomisation groups. FINDINGS: Among 332&#x2009;438 randomised participants (mean age 73&#xb7;7 years [SD 5&#xb7;8]; 161&#x2009;538 [48&#xb7;6%] were female), 276&#x2009;173 (83&#xb7;1%) had low frailty risk, 52&#x2009;395 (15&#xb7;8%) had intermediate frailty risk, and 3861 (1&#xb7;2%) had high frailty risk. The primary endpoint of hospitalisation for influenza or pneumonia occurred in 1424 (0&#xb7;5%) of 276&#x2009;173 participants with low frailty risk, 761 (1&#xb7;5%) of 52&#x2009;395 with intermediate frailty risk, and 163 (4&#xb7;2%) of 3861 with high frailty risk (relative risk [RR] for intermediate vs low frailty risk 2&#xb7;8 [95% CI 2&#xb7;6-3&#xb7;1]; RR for high vs low frailty risk 8&#xb7;2 [7&#xb7;0-9&#xb7;6]). HFRS as a continuous variable significantly modified the effect of HD-IIV versus SD-IIV against the primary endpoint with higher rVE estimates with increasing HFRS (pinteraction=0&#xb7;020). The rVE was 0&#xb7;2% (95% CI -10&#xb7;8 to 10&#xb7;2) among those with low frailty risk, 13&#xb7;1% (-0&#xb7;4 to 24&#xb7;8) among those with intermediate frailty risk, and 19&#xb7;9% (-10&#xb7;3 to 42&#xb7;1) among those with high frailty risk. No significant interaction was observed when HFRS was assessed according to the prespecified categorical frailty groups (pinteraction=0&#xb7;17). The proportion of participants with at least one serious adverse event increased across frailty risk groups (13&#x2009;366 [4&#xb7;8%] of 275&#x2009;795 for low frailty risk, 5475 [10&#xb7;5%] of 52&#x2009;315 for intermediate frailty risk, and 777 [20&#xb7;2%] of 3850 for high frailty risk; p<0&#xb7;0001), with similar proportions of serious adverse events in the HD-IIV and SD-IIV groups for each frailty risk group. INTERPRETATION: Among adults aged 65 years or older in Denmark, frailty risk might modify the effects of HD-IIV versus SD-IIV against hospitalisation for influenza or pneumonia, with higher rVE estimates with increasing frailty risk. These findings might support considering high-dose influenza vaccines for frail older adults. However, effect modification was not evident when frailty was assessed using prespecified categorical subgroups, and subgroup-specific estimates were imprecise, with 95% CIs crossing the null. These results should be considered exploratory, warranting further investigation. FUNDING: The DANFLU-2 trial was funded by Sanofi.

Journal Article↗